Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that low-dose oral minoxidil effectively increased hair count over 24 weeks with mild reductions in blood pressure and minimal adverse effects among participants, suggesting its potential as a safe treatment for hair loss.

Combining PRP with topical minoxidil is most effective for hair growth in androgenetic alopecia.

Spironolactone helps prevent swelling caused by minoxidil in women with hair loss.

This study found that using dual-wavelength low-level laser therapy is more effective for hair regrowth in mice than single-wavelength treatment and significantly better than no treatment, based on 14 days of phototherapy with LED lights.

The study explores the potential effectiveness of low-dose oral minoxidil in treating short anagen hair syndrome, suggesting it may be a viable treatment option despite the condition often resolving spontaneously with puberty.

Low-dose oral minoxidil alone is effective for treating hair loss, but combining it with dutasteride or finasteride may offer better results.

This study found that initiating low-dose oral minoxidil did not significantly change alcohol consumption among 21,971 patients, suggesting a minimal impact on alcohol-related hangover symptoms.

This systematic review and meta-analysis found that adding low-level laser therapy to minoxidil treatment for androgenic alopecia does not significantly enhance hair count or diameter compared to using minoxidil alone.

This letter to the editor discusses blood pressure changes in patients taking low-dose oral minoxidil but reports no new research findings.

This study found that adding low-dose oral minoxidil to standard treatment for lichen planopilaris was safe but did not significantly improve hair density or thickness, although minor hair regrowth was observed in some scarring areas.

This review discusses various applications of low level laser therapy and argues for a holistic evaluation of patients but reports no new clinical findings.

This review discusses the implications of renaming myelodysplastic syndromes as "myelodysplastic neoplasms" and argues that the "low-risk" label may misrepresent patient experiences and hinder research.

This source reports that an international panel of dermatologists has provided a consensus statement to guide clinicians on the off-label use of low-dose oral minoxidil for treating hair loss.

LMWP-PDGFA shows promise for improving hair health and treating hair loss with fewer side effects.

In this study of patients with androgenetic alopecia taking off-label low-dose oral minoxidil, adverse events like dizziness/lightheadedness, hypertrichosis, and extremity edema were observed in 14.9% of patients, with females experiencing more adverse events; higher doses increased dizziness risk, leading researchers to recommend cautious dosing approaches.

This consensus statement provides expert guidance on prescribing low-dose oral minoxidil for hair loss, noting a lack of representation of pediatric specialists and highlighting areas for future research.

In this study, low-level laser/LED therapy significantly increased hair density in patients with androgenetic alopecia compared to placebo over 4 to 26 weeks; however, the efficacy for other alopecia types remains unclear, requiring further research.

This study examined the FDA Adverse Event Reporting System database and found significant associations between low-dose oral minoxidil use and adverse events like pericardial effusion, highlighting the need for caution and recommending the use of the lowest effective dose until more safety data are available.

Both treatment combinations improved hair growth similarly and were safe.

In this case series, low-dose oral metformin was associated with improvements in symptoms and gene expression changes in Black female patients with treatment-resistant central centrifugal cicatricial alopecia, suggesting a potential therapeutic role for metformin in managing this condition.

This study found that bi-weekly 1550nm low-level laser therapy significantly improved hair loss conditions and scalp health in participants, suggesting its potential as an effective non-invasive treatment option.

In this interventional study on female-pattern hair loss, researchers found that fractional CO2 laser therapy alone improved hair growth, as evidenced by increased hair count, thickness, density, and patient satisfaction compared to saline controls. However, the precise mechanisms behind these effects require further investigation.

This study addresses the scarcity of information on the effectiveness and safety of low-dose oral minoxidil for treating COVID-19-associated telogen effluvium, a type of hair loss observed in some patients after COVID-19 infection, but does not report specific results.

This review discusses the consensus reached by international experts on guidelines for prescribing and monitoring low-dose oral minoxidil for hair loss, and reports no new clinical results.

This study found that root hairs of wild-type Arabidopsis grow faster and longer under low potassium stress, with changes in actin filament dynamics and specific regulation by the actin bundling proteins VLN1 and VLN4.

In this study, low-dose oral minoxidil was found to be an effective and safe treatment for androgenetic alopecia, showing comparable outcomes in patients with AGA alone and those with AGA unmasked by telogen effluvium.

In this research, low-fluence light-based hair removal was explored, revealing its potential for at-home use with improvements in efficacy and safety, particularly for dark skin individuals, although further studies are necessary.

This case study involving a 63-year-old woman with female pattern hair loss found that a 3-month regimen of low-dose oral minoxidil increased hair density from 98 to 140 hairs per square centimeter, but caution was advised regarding its safety and efficacy without larger trials.

Low-dose oral minoxidil is generally safe for hypertensive patients with hair loss.

In this study, researchers found that low-dose oral minoxidil for androgenetic alopecia in men generally showed a good safety profile, with hypertrichosis being the most frequent side effect, while systemic side effects like dizziness and hypotension were less common and no life-threatening effects were observed.